Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21578944 | 0.99 | KDM4E (0.55) | KDM4EBCHEADRB2DHODHSMN1; SMN2 | |
| SCHEMBL21578943 | 0.96 | KDM4E (0.51) | KDM4EBCHEADRB2DHODHLMNA | |
| SCHEMBL10879276 | 0.81 | KDM4E (0.64) | KDM4EBCHEADRB2SMN1; SMN2HTT | |
| SCHEMBL21579057 | 0.80 | BCHE (0.37) | KDM4EBCHEADRB2SMN1; SMN2LMNA | |
| SCHEMBL10876683 | 0.80 | KDM4E (0.56) | KDM4EBCHEADRB2DHODHLMNA | |
| SCHEMBL10877567 | 0.77 | KDM4E (0.88) | KDM4EBCHELMNACYP1A2CYP2D6 | |
| SCHEMBL10877574 | 0.77 | KDM4E (0.88) | KDM4EBCHELMNACYP1A2CYP2D6 | |
| SCHEMBL19330018 | 0.77 | KDM4E (0.63) | KDM4EBCHEADRB2SMN1; SMN2NFKB1 | |
| Acetic Acid SCHEMBL19330042 | 0.73 | KDM4E (0.66) | KDM4EBCHEADRB2SMN1; SMN2LMNA | |
| SCHEMBL9768074 | 0.72 | ADRB2 (0.63) | KDM4EBCHEADRB2NFKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | Academic Pharmaceuticals, Incorporated (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210107867-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2021-04-15 | — | — | US | disclosed |
| US-10793519-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INCORPORATED (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190352257-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACADEMIC PHARMACEUTICALS INCORPORATED | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352257-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | SCN5A, CACNA1G, CACNA1H | KDM4E 3169/4885BCHE 4218/4885ADRB2 53/4885 |
| US-20210107867-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | SCN5A, CACNA1G, CACNA1H | KDM4E 3169/4885BCHE 4218/4885ADRB2 53/4885 |
| US-11286235-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | KDM4E 3169/4885BCHE 4218/4885ADRB2 53/4885 |
| US-10793519-B2 | Ultra short acting anti-arrhythmic agents | SCN5A, CACNA1G, CACNA1H | KDM4E 3169/4885BCHE 4218/4885ADRB2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.